123 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
Targets and Cancer Therapeutics that suggest TP53 wild-type status may predict sensitivity to exportin 1 (XPO1) inhibitors selinexor and eltanexor
8-K
EX-10.3
kxk69bux
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-10.2
qxijsss
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-99.1
x4u8dp wtt4bbdxke3k
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
u8azn2t
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
im2mm7u0l frxkigx
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.2
9coj9h wbu0tqacqjz
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
hbk03rq84 d4r6v4j1
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm